title: Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand.
abstract: BACKGROUND
  Thalidomide based regimen is an effective and well tolerated therapy in multiple myeloma (MM) patients, however, there were a small number of studies written about the results of thalidomide therapy in non-transplant MM patients. We therefore conducted a retrospective study of 42 consecutive patients with newly diagnosed and relapsed/refractory MM treated with thalidomide- based induction regimens followed by thalidomide maintenance therapy.
  
  
  RESULTS
  Induction regimens with thalidomide and dexamethasone, and the oral combination of melphalan, prednisolone and thalidomide were administrated in 22 and 16 patients, respectively. The remaining 4 patients received other thalidomide- containing regimens. Twenty-nine patients received thalidomide as a salvage regimen. Twenty-three out of 26 patients achieving complete remission (CR) and very good partial remission (VGPR) received thalidomide maintenance. Of the 41 evaluable patients, median time of treatment was 21 months (3- 45 months), ORR was 92.7% with a 63.4% CR/VGPR. With a median follow up of 23 months, 3-year- PFS and 3-year-OS were 58.6 and 72.6%, respectively. Median time to progression was 42 months. While 3-year-PFS and 3-year-OS in non-transplant patients receiving thalidomide maintenance therapy were 67 and 80%, respectively.
  
  
  CONCLUSIONS
  Prolonged thalidomide therapy enhanced survival rate and less frequently developed serious toxicity in non-transplant multiple myeloma patients.
authors.affiliation: Division of hematology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Thailand. niparuckblue@gmail.com
authors.forename: Pimjai
authors.initials: P
authors.lastname: Niparuck
authors.forename: Ladda
authors.initials: L
authors.lastname: Sorakhunpipitkul
authors.forename: Vichai
authors.initials: V
authors.lastname: Atichartakarn
authors.forename: Suporn
authors.initials: S
authors.lastname: Chuncharunee
authors.forename: Artit
authors.initials: A
authors.lastname: Ungkanont
authors.forename: Pantep
authors.initials: P
authors.lastname: Aungchaisuksiri
authors.forename: Teeraya
authors.initials: T
authors.lastname: Puavilai
authors.forename: Saengsuree
authors.initials: S
authors.lastname: Jootar
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D020360:Neoadjuvant Therapy; D012008:Recurrence; D012189:Retrospective Studies; D016879:Salvage Therapy; D016019:Survival Analysis; D013785:Thailand; D013792:Thalidomide / Q000008:administration & dosage*; D014180:Transplantation; D016896:Treatment Outcome
chemical_list: D013792:Thalidomide